home / stock / fulc / fulc news

FULC News and Press, Fulcrum Therapeutics Inc.

Stock Information
Company Name: Fulcrum Therapeutics Inc.
Stock Symbol: FULC
Market: NYSE
Website: fulcrumtx.com
Menu
FULC FULC Quote FULC Short FULC News FULC Articles FULC Message Board
Get FULC Alerts

News, Short Squeeze, Breakout and More Instantly...
FULC - Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

2024-06-14 14:38:51 ET Summary Avidity Biosciences, Inc.'s FORTITUDE trial of AOC 1020 in treating FSHD showed promising reductions in DUX4 gene expression and improvements in muscle function. The trial reported favorable safety and tolerability, with no serious adverse events or ...
FULC - Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...

FULC - Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...

FULC - Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data

2024-05-13 17:52:17 ET More on Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate ...
FULC - INFN, VYGR and AMSC are among after hour movers

2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...

FULC - Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript

2024-05-13 10:38:01 ET Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript May 13, 2024, 08:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Paul Bruno - SVP of Business and Corporate Development Iain Fraser - SVP o...

FULC - Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate

2024-05-13 10:09:30 ET More on Sanofi, Fulcrum Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: ARM, ZK...
FULC - Fulcrum Therapeutics GAAP EPS of -$0.43 in-line

2024-05-13 07:22:58 ET More on Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript Fulcrum hits 52-week high as CEO buys shares Seeking Alpha’s Quant Rating on Fulcrum Therapeutics Historical earnings data for Fulcru...

FULC - Expected US Company Earnings on Monday, May 13th, 2024

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

FULC - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourt...
Next 10